retatrutide blindness Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide for Weight Loss: TRIUMPH-1

Endocrinology 149 , 20382047 (2008)

At 68 weeks, the treatment-regimen estimand results were -20.0% (9 mg dose, approximately 50.5 pounds) and -23.7% (12 mg dose, approximately 60 pounds)

Florencia Z, Christos M

Advocates have also correctly noted that there isnt a single other medicine where Medicare considers the cost of a drug relative to its potential savings in determining coverage but maybe Medicare should start doing so

A Vicious Circle Between Insulin Resistance and Inflammation in Nonalcoholic Fatty Liver Disease

Providers cannot perform physical exams, conduct in-person follow-ups, or observe you directly